Al-Ola Abdallah, Associate Professor Of Medicine at University of Kansas Medical Center, shared on X:
“The apparent flattening of PFS curves beyond ~18 months with BCMA bispecifics in RRMM raises a question:
Could combinations enable fixed-duration therapy?
Encouraging durability IMO.”
Title: Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals
Authors: Jordan Snyder, Shebli Atrash, Barry Paul, Abdullah Mohammad Khan, Alma Habib, Hira Shaikh, Christopher Strouse, Omar Alkharabsheh, Anita Mazloom, Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Anas Zayad, Joseph McGuirk, Yun Kyoung Tiger, Mansi R. Shah, Al-Ola Abdallah.
Read the full article.
This also can be interesting:
Myeloma Paper of the Day, October 25th, Suggested by Robert Orlowski
